
|Articles|November 15, 2007
First-line treatment for neovascular AMD
Combination therapy using photodynamic therapy and verteporfin (Visudyne, Novartis) as well as bevacizumab (Avastin, Genentech) can be effective in patients with age-related macular degeneration (AMD), particularly when patients are naïve to treatment, according to results from a patient registry.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Physician perspective: Glaucoma eye drops are here to stay
2
Commercial red light devices for myopia may exceed safety limits
3
SparingVision completes PRODYGY trial patient dosing with SPVN06
4
No significant visual gains seen with PDE6A gene supplementation in early-phase trial
5




























